Published in Mol Cell Biol on October 01, 2004
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets (2012) 1.01
Androgen receptor drives cellular senescence. PLoS One (2012) 0.89
Dlx genes, p63, and ectodermal dysplasias. Birth Defects Res C Embryo Today (2005) 0.84
p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY) (2016) 0.78
Epigenetic Regulation of Epidermal Stem Cell Biomarkers and Their Role in Wound Healing. Int J Mol Sci (2015) 0.75
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell (1998) 11.54
A model for p53-induced apoptosis. Nature (1997) 11.38
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27
p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev (2004) 6.40
Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol (1999) 5.78
Principles of tumor suppression. Cell (2004) 5.52
p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature (1997) 5.42
Tumor surveillance via the ARF-p53 pathway. Genes Dev (1998) 5.11
Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J (1999) 4.69
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet (2002) 3.57
Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell (2003) 3.42
Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med (1998) 3.23
The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol (2003) 3.00
Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol (2001) 2.96
Regulation of the p53 tumor suppressor protein. J Biol Chem (1999) 2.94
Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell (1999) 2.93
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell (2003) 2.54
p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene (2001) 2.40
Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol (2000) 2.34
Regulation of the human hsp70 promoter by p53. Science (1993) 2.02
p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol Cell (2003) 1.92
Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol (2002) 1.89
Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res (2000) 1.88
A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol (2002) 1.73
How to activate p53. Curr Biol (2000) 1.70
Mdm2 binds p73 alpha without targeting degradation. Oncogene (1999) 1.62
Splitting p63. Am J Hum Genet (2002) 1.62
Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene (2001) 1.55
Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. Trends Mol Med (2002) 1.46
Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol (2000) 1.28
Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol Cell Biol (2002) 1.23
The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem (2001) 1.22
p53 Family members p63 and p73 are SAM domain-containing proteins. Protein Sci (1999) 1.19
Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. Exp Cell Res (2000) 1.02
Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3, and Sp1-like factors. Biochem Biophys Res Commun (2002) 1.00
Association of p14ARF with the p120E4F transcriptional repressor enhances cell cycle inhibition. J Biol Chem (2002) 0.98
Differential regulation of p63 and p73 expression. Oncogene (2003) 0.97
Switch from p53 to MDM2 as differentiating human keratinocytes lose their proliferative potential and increase in cellular size. Oncogene (2000) 0.95
The human tumor suppressor arf interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein. J Biol Chem (2001) 0.95
Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1. J Biol Chem (2003) 0.94
The regulation of APAF1 expression during development and tumourigenesis. Apoptosis (2002) 0.83
Suppression of Ras-mediated NIH3T3 transformation by p19ARF does not involve alterations of cell growth properties. Oncogene (1999) 0.78
Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell (2011) 2.71
TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol (2013) 2.62
Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc Natl Acad Sci U S A (2003) 2.39
Itch/AIP4 associates with and promotes p63 protein degradation. Cell Cycle (2006) 1.91
Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol (2002) 1.89
Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol (2008) 1.82
Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. EMBO Rep (2002) 1.79
A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias. J Clin Invest (2010) 1.73
Homeodomain protein Dlx3 induces phosphorylation-dependent p63 degradation. Cell Cycle (2009) 1.62
TRIM8 modulates p53 activity to dictate cell cycle arrest. Cell Cycle (2012) 1.56
Regulation of Dlx5 and Dlx6 gene expression by p63 is involved in EEC and SHFM congenital limb defects. Development (2008) 1.55
Apoptosis inhibition in cancer cells: a novel molecular pathway that involves BAG3 protein. Int J Biochem Cell Biol (2007) 1.44
Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Proc Natl Acad Sci U S A (2011) 1.42
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol (2007) 1.25
The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem (2001) 1.22
Claudin-1 is a p63 target gene with a crucial role in epithelial development. PLoS One (2008) 1.20
The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab (2006) 1.18
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med (2012) 1.14
The protein stability and transcriptional activity of p63alpha are regulated by SUMO-1 conjugation. Cell Cycle (2005) 1.12
Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate (2006) 1.12
UbcH10 is overexpressed in malignant breast carcinomas. Eur J Cancer (2007) 1.10
MDM2 and Fbw7 cooperate to induce p63 protein degradation following DNA damage and cell differentiation. J Cell Sci (2010) 1.09
Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res (2005) 1.09
Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic mice. Proc Natl Acad Sci U S A (2004) 1.08
Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. Proc Natl Acad Sci U S A (2005) 1.07
Regulation of the cyclin-dependent kinase inhibitor p57Kip2 expression by p63. Cell Cycle (2005) 1.07
Homeobox gene Dlx3 is regulated by p63 during ectoderm development: relevance in the pathogenesis of ectodermal dysplasias. Development (2007) 1.02
Transcriptional regulation of the human tumor suppressor p14(ARF) by E2F1, E2F2, E2F3, and Sp1-like factors. Biochem Biophys Res Commun (2002) 1.00
Metaplastic breast carcinoma on fine-needle cytology samples: a report of three cases. Diagn Cytopathol (2005) 0.99
Quantitative proteomics identifies Gemin5, a scaffolding protein involved in ribonucleoprotein assembly, as a novel partner for eukaryotic initiation factor 4E. J Proteome Res (2006) 0.99
The finger subdomain of yeast telomerase cooperates with Pif1p to limit telomere elongation. Nat Struct Mol Biol (2006) 0.97
p66Shc deletion confers vascular protection in advanced atherosclerosis in hypercholesterolemic apolipoprotein E knockout mice. Endothelium (2008) 0.96
Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1. J Biol Chem (2003) 0.94
Evidence for modulation of BAG3 by polyomavirus JC early protein. J Gen Virol (2009) 0.92
The promiscuity of ARF interactions with the proteasome. FEBS Lett (2008) 0.90
Downregulation of DeltaNp63alpha in keratinocytes by p14ARF-mediated SUMO-conjugation and degradation. Cell Cycle (2009) 0.90
Induction of Id-1 by FGF-2 involves activity of EGR-1 and sensitizes neuroblastoma cells to cell death. J Cell Physiol (2011) 0.90
Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. Clin Endocrinol (Oxf) (2008) 0.89
Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction. Eur J Cancer (2006) 0.88
BMP-mediated functional cooperation between Dlx5;Dlx6 and Msx1;Msx2 during mammalian limb development. PLoS One (2013) 0.88
Endocrine carcinoma of the major papilla: report of two cases and review of the literature. Surg Oncol (2009) 0.88
p53: The pivot between cell cycle arrest and senescence. Cell Cycle (2010) 0.88
PED/PEA-15 controls fibroblast motility and wound closure by ERK1/2-dependent mechanisms. J Cell Physiol (2012) 0.87
A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes. Oncogene (2005) 0.86
Complete polyethylene wear-through and secondary breakage of the expansion cup in a ceramic-polyethylene total hip. Arch Orthop Trauma Surg (2010) 0.86
Identification of DeltaNp63alpha protein interactions by mass spectrometry. J Proteome Res (2010) 0.85
The Hay Wells syndrome-derived TAp63alphaQ540L mutant has impaired transcriptional and cell growth regulatory activity. Cell Cycle (2006) 0.84
BAG3 expression is sustained by FGF2 in neural progenitor cells and impacts cell proliferation. Cell Cycle (2010) 0.84
Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants. Cell Cycle (2006) 0.83
Erythropoietin and erythropoietin receptor system in a large uterine myoma of a patient with myomatous erythrocytosis syndrome: possible relationship with the pathogenesis of unusual tumor size. Hum Pathol (2005) 0.82
The p63 protein isoform ΔNp63α modulates Y-box binding protein 1 in its subcellular distribution and regulation of cell survival and motility genes. J Biol Chem (2012) 0.82
Cancer biology: The director's cut. Nature (2012) 0.81
Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease. Mol Cancer (2014) 0.80
A dominant mutation etiologic for human tricho-dento-osseous syndrome impairs the ability of DLX3 to downregulate ΔNp63α. J Cell Physiol (2011) 0.80
Mimicking p14ARF phosphorylation influences its ability to restrain cell proliferation. PLoS One (2013) 0.80
Omics underpins novel clues on VDR chemoprevention target in breast cancer. OMICS (2011) 0.79
CELLFOOD™ induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways. J Exp Clin Cancer Res (2014) 0.78
Expression of cyclin-D1 in uveal malignant melanoma. Anticancer Res (2003) 0.78
Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior. Anticancer Res (2004) 0.78
Epithelioid myoepithelioma of lacrimal gland. Virchows Arch (2004) 0.78
A biochemical and cellular approach to explore the antiproliferative and prodifferentiative activity of Aloe arborescens leaf extract. Phytother Res (2013) 0.77
Lactobacillus gasseri SF1183 affects intestinal epithelial cell survival and growth. PLoS One (2013) 0.76
Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig (2005) 0.76
A regulatory mechanism involving TBP-1/Tat-Binding Protein 1 and Akt/PKB in the control of cell proliferation. PLoS One (2011) 0.76
Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine. Cancer Res (2013) 0.75
Expression of proliferating cell nuclear antigen and bcl-2 during a pseudomenopausal state induced by presurgical treatment of uterine leiomyomas with gonadotropin-releasing hormone analogues plus tibolone. Int J Gynecol Pathol (2005) 0.75
Hysteroscopic diagnosis of stromomyoma. J Minim Invasive Gynecol (2010) 0.75